Improvement of insulin resistance by a new insulin secretagogue, nateglinide - Analysis based on the homeostasis model

Diabetes Research and Clinical Practice

Volumn 62, Issue 2, 2003, Pages 87-94

  Shiba, Teruo ^a  

^a MITSUI MEMORIAL HOSPITAL   (Japan)

Author keywords

HOMA IR; Insulin resistance; Nateglinide

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; NATEGLINIDE;

ADULT; AGED; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; REDUCTION;

EID: 0142138173     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(03)00169-4     Document Type: Article

References (26)

1. Weyer C., Bogardus C., Mott D.M., Pratley R.E. The natural history of insulin secretory dysfunction and resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 104:1999;787-794.
2. Luzi L., DeFronzo R.A. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am. J. Physiol. 257:1989;E241-E246.
3. Malaisse W.J. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm. Metab. Res. 27:1995;263-266.
4. Akiyoshi M., Kakie M., Nakazaki M., Tanaka H. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells. Am. J. Physiol. 268:1995;E185-193.
5. Hanefeld M., Dickinson S., Bouter K.P., Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care. 23:2000;202-207.
6. Uchino H., Niwa M., Shimizu T., Nishiyama K., Kawamori R. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocr. J. 47:2000;639-641.
7. Donahue R.P., Abbott R.D., Reed D.M., Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry Honolulu heart program. Diabetes. 36:1987;688-692.
8. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 48:1999;937-942.
9. Tominaga M., Igarashi K., Eguchi H., Kato T., Manaka H., Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care. 22:1999;920-924.
10. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 354:1999;617-621.
11. Kashiwagi A. Assessment of insulin resistance by routine laboratory tests. Intern. Med. 87:2001;855-858.
12. Vaag A., Henriksen J.E., Madsbad S., Holm N., Beck-Nielsen H. Insulin secretion, insulin action and hepatic glucose production in identical twins for non-insulin-dependent diabetes mellitus. J. Clin. Invest. 95:1995;690-698.
13. Elbein S.C., Hasstedt S.J., Wegner K., Kahn S.E. Heritability of pancreatic β-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J. Clin. Endocrinol. Metab. 84:1999;1398-1403.
14. Del Prato S., Tiengo A. The importance of first-phase insulin secretion: implication for the therapy of type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 17:2001;164-174.
15. Mitrakou A., Kelly D., Mokan M., et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. New Engl. J. Med. 326:1992;22-29.
16. Stumvoll M., Jacob S. Multiple sites of insulinresistance: muscle, liver and adipose tissue. Exp. Clin. Endocrinol. Diabetes. 107:1999;107-110.
17. Basu A., Alzaid A., Dinneen S., Caumo A., Cobelli C., Rizza R.A. Effect of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and non diabetic humans in the presence of differing degrees of insulin resistance. J. Clin. Invest. 97:1996;2351-2361.
18. 1c. Diabetes Care. 23:2000;1236-1241.
19. Robertson R.P., Olson L.K., Zhang H.-J. Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes. 43:1994;1085-1089.
20. Takami K., Odaka H., Tsukuda R., Matsuo T. Antidiabetic actions of a disaccharidase inhibitor, AO-128, in spontaneously diabetic (GK) rats. Jpn. Pharmacol. Ther. 19:1991;4457-4467.
21. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:1985;412-419.
22. Nagasaka S., Iwamoto Y., Ishikawa S., Kuzuya T., Saito T. Efficacy of troglitazone measured by insulin resistance index. Lancet. 350:1997;184.
23. Rosenblatt S., Miskin B., Glazer N.B., Prince M.J., Robertson K.E. The impact of pioglitazone on glycemic control and atherogenic dislipidemia in patients with type 2 diabetes mellitus. Coron. Artery Dis. 12:2001;413-423.
24. Haffner S.M., Kennedy E., Gonzalez C., Stern M.P., Miettinen H. A prospective analysis of the HOMA model-the Mexico City diabetes study. Diabetes Care. 19:1996;1138-1141.
25. Emoto E., Kawagishi T., Nishizawa Y., et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 22:1999;818-822.
26. Bonora E., Saggiani F., Targhier G., et al. Homeostaaasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care. 23:2000;57-63.